Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) has approved its Alhemo (concizumab-mtci) ...

在一项新的研究中，来自印度韦洛尔基督教医学院等研究机构的研究人员发现，慢病毒载体可成功用于为严重血友病A患者提供基因治疗。他们为腺相关病毒（AAV）介导的基因治疗提供了一种潜在的替代方案，解决了将事先存在抗AAV抗体的患者排除在基因治疗对象之外的问题 ...

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed ...

A pair of studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition highlight continuing ...

Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia ...

Research led by Christian Medical College in Vellore, India, has demonstrated the successful use of lentiviral vectors to ...

A seminar titled 'Hemophilia Awareness' was held here at Govt College Women University Sialkot (GCWUS) to educate ...

India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...

Metagenomi (MGX) presented updated preclinical NHP data for its hemophilia A program in an oral presentation (link here) ...

MGX-001 bioengineered FVIII construct exhibited higher FVIII activity at similar integration rates compared to wild type FVIII construct in preclinical studies; program on track for IND filing in 2026 ...